Watson Boosts Women’s Health Holdings In $305M Uteron Deal

Law360, New York (January 23, 2013, 3:32 PM EST) -- Watson Pharmaceuticals Inc. has acquired Uteron Pharma SA in a deal valued at $305 million with the strategic goal of expanding the Parsippany, N.J.-based company's women’s health products, according to a statement released Wednesday.

Watson will pay $150 million in cash up front for Uteron, then will pay up to $155 million in potential future milestone payments, the statement says. By acquiring Uteron, which is based in Belgium, Watson will be able to market the products in Uteron’s pipeline, including a long-term contraceptive device and a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.